Kymera Therapeutics annual total assets
2019
2020
2021
2022
2023
2024
2025
Kymera Therapeutics Total Assets Growth & History (KYMR)
Kymera Therapeutics's total assets was $1.74B for fiscal 2025.
View full Kymera Therapeutics company overviewKymera Therapeutics annual total assets history
| Fiscal year | Period ended | Total assets | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $1.74B | $764.8M | +78.20% |
| 2024 | 2024-12-31 | $978.0M | $402.3M | +69.87% |
| 2023 | 2023-12-31 | $575.8M | −$27.4M | −4.54% |
| 2022 | 2022-12-31 | $603.1M | −$2.8M | −0.46% |
| 2021 | 2021-12-31 | $605.9M | $118.7M | +24.37% |
| 2020 | 2020-12-31 | $487.2M | $370.5M | +317.45% |
| 2019 | 2019-12-31 | $116.7M | — | — |
Kymera Therapeutics quarterly total assets
Q4.19
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Total assets | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $1.65B | $514.4M | +45.48% |
| Q1 2026 | 2026-03-31 | $1.67B | $750.7M | +81.75% |
| Q4 2025 | 2025-12-31 | $1.74B | $764.8M | +78.20% |
| Q3 2025 | 2025-09-30 | $1.10B | $67.2M | +6.49% |
| Q2 2025 | 2025-06-30 | $1.13B | $305.0M | +36.93% |
| Q1 2025 | 2025-03-31 | $918.3M | $50.1M | +5.77% |
| Q4 2024 | 2024-12-31 | $978.0M | $402.3M | +69.87% |
| Q3 2024 | 2024-09-30 | $1.03B | $482.5M | +87.34% |
| Q2 2024 | 2024-06-30 | $826.0M | $244.1M | +41.94% |
| Q1 2024 | 2024-03-31 | $868.3M | $254.3M | +41.43% |
| Q4 2023 | 2023-12-31 | $575.8M | −$27.4M | −4.54% |
| Q3 2023 | 2023-09-30 | $552.4M | −$86.1M | −13.48% |
| Q2 2023 | 2023-06-30 | $581.9M | $58.5M | +11.18% |
| Q1 2023 | 2023-03-31 | $613.9M | $50.8M | +9.03% |
| Q4 2022 | 2022-12-31 | $603.1M | −$2.8M | −0.46% |
| Q3 2022 | 2022-09-30 | $638.5M | −$4.0M | −0.62% |
| Q2 2022 | 2022-06-30 | $523.4M | $89.0M | +20.50% |
| Q1 2022 | 2022-03-31 | $563.1M | $98.5M | +21.20% |
| Q4 2021 | 2021-12-31 | $605.9M | $118.7M | +24.37% |
| Q3 2021 | 2021-09-30 | $642.5M | $135.1M | +26.63% |
| Q2 2021 | 2021-06-30 | $434.4M | — | — |
| Q1 2021 | 2021-03-31 | $464.6M | — | — |
| Q4 2020 | 2020-12-31 | $487.2M | $370.5M | +317.45% |
| Q3 2020 | 2020-09-30 | $507.4M | — | — |
| Q4 2019 | 2019-12-31 | $116.7M | — | — |
Kymera Therapeutics total assets trends
Over the last five fiscal years, Kymera Therapeutics's total assets increased from $487.2M to $1.74B, a change of $1.26B. The latest reported quarter, Q2 2026, shows $1.65B.
About the metric
What total assets mean
Total assets are the resources a company controls at a reporting-period end, including cash, investments, receivables, inventory, property, intangible assets, and other reported assets. The composition of assets differs substantially by industry.
Calculation and source
SEC-reported total assets
TickerStat uses total assets reported in company SEC filings. When a filer provides the equivalent balance-sheet total as liabilities and equity, that reported amount is used because total assets must equal total liabilities plus equity. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Kymera Therapeutics source filings ↗